The Eshelman Institute for Innovation has announced the recipients of its 2023 therapeutics grant cycle. The Eshelman Institute was established in 2014 with a $100 million commitment from Fred Eshelman, PharmD. The institute provides grant funding, project management support, competitive landscape analysis, the path to market assistance and capital investment connections to faculty and staff across UNC-Chapel Hill.
The Eshelman Institute works with Carolina faculty who are collaborating with scientists and health care providers both inside and outside UNC-Chapel Hill, including academia, industry and foundations.
This past winter the Eshelman Institute ran their annual therapeutic grant RFP, and have now selected their grant recipients. To learn more about these projects, please visit this website.
2023 Grant Recipients:
T Cell Immunotherapies Targeting HLA-E Antigens for the Clearance of EBV- and HTLV-Associated Malignancies
Paul Armistead, MD, PhD
UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center
Nilu Goonetilleke, PhD
UNC School of Medicine, Microbiology and Immunology
Inhibiting Aquaporin-4: A New Approach for the Treatment of Stroke and CNS Injuries
Kevin Frankowski, PhD
UNC Eshelman School of Pharmacy, Center for Integrative Chemical Biology and Drug Discovery
Rosyln Bill, PhD
Aston University, College of Health & Life Sciences
Follow on Funding: Development of Novel Therapeutics for Multiple Myeloma
Lindsey James, PhD
UNC Eshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry
Restoring Lysosome Function Using a Therapeutic Antibody to Prevent Disease Flare in Systemic Lupus Erythematosus
Barbara Vilen, PhD
UNC School of Medicine, Department of Microbiology and Immunology
Anyone interested in learning more about the Eshelman Institute can email EshelmanInstitute@unc.edu.